Skip to main content

Isopropylphenidate Facts

Stimulant; Phenidate; Dopamine reuptake inhibitor

Description

Isopropylphenidate — also known as IPH — is a synthetic stimulant of the substituted phenidate class. It blocks the brain's dopamine recycling system, raising dopamine levels in the circuits that drive motivation and attention.[1]

Subjective effects include enhanced focus, faster thinking, increased motivation, and mild cognitive euphoria. The experience feels like clean mental drive — task engagement and mental clarity without the physical intensity or emotional warmth of amphetamines.

IPH carries moderate psychological dependence liability; no lethal dose has been established in any species.safety citation needed Cardiovascular strain — elevated heart rate and blood pressure — is the primary acute risk, scaling with dose; combining it with stimulants or MAOIs amplifies this danger.[2]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 2 mgLight5 – 15 mgCommon15 – 25 mgStrong25 – 45 mgHeavy45+ mg

Starts in 10 – 30 minLasts 3.5 – 6 hoursAfter-effects 1 – 4 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Low
Psychological dependence
Moderate
Withdrawal
Mild
Compulsive redosing
Moderate

Tolerance

Builds
Moderate
Fully resets after
10.5 days
Carries over to
methylphenidate; amphetamines; cocaine; other dopaminergic stimulants

Effectslikely at a common dose

Body
Appetite suppression; Insomnia; Stimulation; Wakefulness; +18 possible, including Heart rate perception changes, Muscle tension, Excessive sweating
Thinking
none likely · 20 possible, including Compulsive redosing urge, Thought loops
Feeling
none likely · 9 possible, including Anxiety, Anhedonia, Depression
Self
none likely · 10 possible, including Craving, Ego inflation, Compulsive repetitive behavior

Who shouldn't take it

Absolute
Severe cardiovascular disease; Active psychosis or psychotic disorders; MAOI use
Relative
Seizure disorders; Anxiety disorders; History of substance use disorders; Hyperthyroidism; Glaucoma

Combinations62 recorded

Lethal (2)
Ibogaine; Tramadol
Dangerous (29)
Alpha-2 adrenergic receptor antagonist; Amphetamines; Benzodiazepines, Barbiturates; Ephedrine, Pseudoephedrine; Local anesthetics; MAOIs; MDMA, Amphetamines; MDMA, MDA; NDRIs (Wellbutrin); NRIs; Opioids; SSRIs; Stimulants; Anticholinergics; Antipsychotics; Buspirone; Caffeine; Dopamine agonists; DXM; GHB, Baclofen; GHB, GBL; Ketamine, DXM, PCP; Lithium; NSAIDs; and 5 more, see full page
Caution (28)
See full page: psychedex.org/substances/isopropylphenidate
Not graded (3)
Not listed never means safe.

Seek help immediately if

  • Chest pain; racing, pounding, or irregular heartbeat
  • Very high body temperature; heavy sweating; hot, flushed skin
  • Severe agitation, paranoia, panic, or confusion
  • Severe headache; muscle rigidity or twitching
  • Seizures
  • Signs of stroke — face drooping, one-sided weakness, slurred speech
  • Difficulty breathing; collapse or unconsciousness

What to do

  1. Call emergency services for chest pain, overheating, seizure, or unresponsiveness
  2. Move them to a cool, quiet place and reduce stimulation
  3. Cool the body — remove excess clothing, apply cool damp cloths, fan them
  4. Keep them calm; reassure — panic worsens the cardiovascular strain
  5. If seizing, protect from injury (don't restrain); recovery position afterward
  6. Monitor breathing and be ready to give rescue breaths / CPR

Most stimulant overdoses settle with cooling, a calm environment, and time. The medical danger is hyperthermia, cardiac events (arrhythmia, heart attack, stroke), and seizures — get help immediately if any appear.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Markowitz JS, Zhu HJ, Patrick KS (2013) Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability — Journal of Child and Adolescent Psychopharmacology doi:10.1089/cap.2013.0074
  2. [2]
    ^Spiller HA, Hays HL, Aleguas A (2013) Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. — CNS Drugs doi:10.1007/s40263-013-0084-8
Print version
Report an issue